Address

Other Office
3130 Highland Avenue
Suite 3205
Cincinnati, OH 45219
United States

Open Map


VCID: 30306
    Profile

    Corporate information

    Official name
    Charter Life Sciences Limited Partnership

    Registration country
    Investment activity status
    Active investor

    Company type

    Venture capital fund with a focus on clinical stage life sciences

    Fund terms

    Fund type

    Funding rounds

    Fund Closing USD 66,300,000


    USD 66,300,000 (31 Dec 2004)

    Fund Closing USD 30,000,000


    USD 30,000,000 (1 Mar 2004)

    Fund Closing USD 100,000,000


    USD 100,000,000

    Selected investments

    Country Date Notes
    Xlumena Inc
    Xlumena is a medical device company.
    United States 1 Apr 2011 Series B
    Great Lakes Pharmaceuticals Inc
    Developer of an anti-infective lock solution to address in-dwelling venous catheter mediated infection.
    United States 1 Aug 2010 Series B
    APT Pharmaceuticals Inc
    A pharmaceutical company focused on repurposing well-characterized drugs for under-served populations.
    United States 1 Sep 2008 Series A
    Initial investment. Round participant. Active
    Mirabilis Medica Inc
    Developer of non-invasive ultrasound technology for the treatment of uterine fibroids
    United States N/A
    Barrx Medical Inc
    Minimally invasive placed single use disposable medical device for the treatment of Barrett’s esophagus.
    United States N/A
    Active
    Intarcia Therapeutics Inc
    A biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the t
    United States N/A
    Revascular Therapeutics Inc
    United States N/A
    CoMentis Inc
    United States N/A
    KFx Medical Corp
    United States N/A
    EnteroMedics Inc
    Develops therapeutic devices for the treatment of obesity. Its VSM technology uses electrical signals, delivered by an implantable electrode array, to
    United States N/A
    Asthmatx Inc
    United States Series D
    Kereos Inc
    Kereos, Inc. develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease.
    United States N/A

    DISCLAIMER: This chart is based on a limited amount of data and may change once additional information has been added. We are working hard to ensure the completeness of the data. If you want to assist us in our work, please contact us using this form.